Abstract
Optimal identification of the risk of developing cardiotoxicity upon trastuzumab (TZM) treatment appears necessary as this risk may impair treatment compliance and compromise long-term recovery. To better understand and predict cardiac toxicity, the molecular mechanisms underlying this phenomenon need to be known. HER2 is present at the cell surface of cardiomyocytes. Neuregulin is produced by cardiac endothelial cells and binds to HER4, thus leading to dimerization with HER2 and subsequent cell signaling necessary for normal cardiac function. Decreasing HER2 activity has a major impact on cardiomyocyte function. However, the precise molecular mechanisms responsible for TZM-induced cardiac dysfunction are still unclear. This mini-review aims to summarize genetic, pharmacological and medical data helping to identify mechanisms that could explain cardiotoxicity. Of potential interest, these mechanisms highlight the importance of HER2 genetic polymorphism (Val655Ile) in the identification of patients at risk of developing TZMinduced cardiac effects.
Keywords: Cardiotoxicity, genetic polymorphism, HER2, personalized treatment, trastuzumab.
Current Drug Targets
Title:Trastuzumab-Induced Cardiotoxicity: Is it a Personalized Risk?
Volume: 15 Issue: 13
Author(s): Gerard A. Milano, Emilie Serres, Jean-Marc Ferrero and Joseph Ciccolini
Affiliation:
Keywords: Cardiotoxicity, genetic polymorphism, HER2, personalized treatment, trastuzumab.
Abstract: Optimal identification of the risk of developing cardiotoxicity upon trastuzumab (TZM) treatment appears necessary as this risk may impair treatment compliance and compromise long-term recovery. To better understand and predict cardiac toxicity, the molecular mechanisms underlying this phenomenon need to be known. HER2 is present at the cell surface of cardiomyocytes. Neuregulin is produced by cardiac endothelial cells and binds to HER4, thus leading to dimerization with HER2 and subsequent cell signaling necessary for normal cardiac function. Decreasing HER2 activity has a major impact on cardiomyocyte function. However, the precise molecular mechanisms responsible for TZM-induced cardiac dysfunction are still unclear. This mini-review aims to summarize genetic, pharmacological and medical data helping to identify mechanisms that could explain cardiotoxicity. Of potential interest, these mechanisms highlight the importance of HER2 genetic polymorphism (Val655Ile) in the identification of patients at risk of developing TZMinduced cardiac effects.
Export Options
About this article
Cite this article as:
Milano A. Gerard, Serres Emilie, Ferrero Jean-Marc and Ciccolini Joseph, Trastuzumab-Induced Cardiotoxicity: Is it a Personalized Risk?, Current Drug Targets 2014; 15 (13) . https://dx.doi.org/10.2174/1389450115666141114151911
DOI https://dx.doi.org/10.2174/1389450115666141114151911 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Antisense Oligonucleotide-Mediated Exon Skipping for Duchenne Muscular Dystrophy: Progress and Challenges
Current Gene Therapy Mechanisms and Medical Management of Exercise Intolerance in Hypertrophic Cardiomyopathy
Current Pharmaceutical Design Dipyridamole: A Drug with Unrecognized Antioxidant Activity
Current Topics in Medicinal Chemistry Cardio-Protective Effects of Sodium-Glucose Co-Transporter 2 Inhibitors: Focus on Heart Failure
Current Pharmaceutical Design Potential New Targets for Antithrombotic Therapy
Current Pharmaceutical Design Cellular and Molecular Mechanisms of Low Cardiac Output Syndrome after Pediatric Cardiac Surgery
Current Vascular Pharmacology In vivo Optical Molecular Imaging of Cardiovascular Diseases: Long Road Ahead
Current Molecular Imaging (Discontinued) The Role of Asymmetric Dimethylarginine (ADMA) in Endothelial Dysfunction and Cardiovascular Disease
Current Cardiology Reviews Drugs Targeting Parasite Lysosomes
Current Pharmaceutical Design Acute Myocarditis in Children: An Overview of Treatment and Recent Patents
Recent Patents on Inflammation & Allergy Drug Discovery Recent Advances in Molecular Modeling and Medicinal Chemistry Aspects of Phospho-Glycoprotein&#
Current Drug Metabolism Bioenergetics and Mitochondrial Dysfunction in Aging: Recent Insights for a Therapeutical Approach
Current Pharmaceutical Design Treating Heart Failure with Preserved Ejection Fraction Related to Arterial Stiffness. Can we Kill Two Birds With One Stone?
Current Vascular Pharmacology Indications for Heart Transplantation in Congenital Heart Disease
Current Cardiology Reviews Role of Oxidative Stress in Development of Cardiovascular Complications in Diabetes Mellitus
Current Vascular Pharmacology The Diagnostic and Prognostic Value of Brain Natriuretic Peptide and Aminoterminal (nt)-pro Brain Natriuretic Peptide
Current Pharmaceutical Design Circadian Rhythm in Cytokines Administration
Mini-Reviews in Medicinal Chemistry Highly Active Antiretroviral Therapy and Cardiovascular Complications in HIV-Infected Patients
Current Pharmaceutical Design Utility of the Electrocardiogram in Drug Overdose and Poisoning: Theoretical Considerations and Clinical Implications
Current Cardiology Reviews Potential of Resveratrol in Preventing the Development of Heart Failure
Current Chemical Biology